Genmab A/S (OTCMKTS:GNMSF - Get Free Report) issued its quarterly earnings results on Thursday. The company reported $3.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.88 by $1.17, Zacks reports. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%. The business had revenue of $765.14 million during the quarter, compared to analyst estimates of $761.09 million.
Genmab A/S Price Performance
Shares of OTCMKTS:GNMSF traded up $4.32 during trading on Tuesday, hitting $197.45. 14,803 shares of the company's stock were exchanged, compared to its average volume of 3,030. The business's 50-day simple moving average is $198.49 and its 200 day simple moving average is $207.34. The company has a market cap of $13.05 billion, a price-to-earnings ratio of 11.27 and a beta of 1.02. Genmab A/S has a 52-week low of $170.00 and a 52-week high of $305.09.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
